KRRO
KRRO
NASDAQ · Biotechnology

Korro Bio Inc

$14.75
+0.02 (+0.14%)
Financial Highlights (FY 2026)
Revenue
10.62M
Net Income
-194,749,710
Gross Margin
44.7%
Profit Margin
-1,834.5%
Rev Growth
-23.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 44.7% 44.7% 36.3% 36.3%
Operating Margin -1,906.4% -1,715.7% -18.2% -15.4%
Profit Margin -1,834.5% -1,742.8% -21.6% -18.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 10.62M 13.81M 16.40M 15.17M
Gross Profit 4.75M 6.18M 5.95M 5.50M
Operating Income -202,371,336 -236,907,131 -2,982,822 -2,336,962
Net Income -194,749,710 -227,984,832 -3,544,265 -2,816,245
Gross Margin 44.7% 44.7% 36.3% 36.3%
Operating Margin -1,906.4% -1,715.7% -18.2% -15.4%
Profit Margin -1,834.5% -1,742.8% -21.6% -18.6%
Rev Growth -23.1% -23.1% +19.8% +8.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 18.25M 14.30M
Total Equity — — 49.68M 50.11M
D/E Ratio — — 0.37 0.29
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -195,272,451 -241,296,603 -3,398,004 -2,964,187
Free Cash Flow — — -3,167,900 -2,994,560